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Dominant negative mutations in the transcription-factor STAT3 underlie the rare primary
immunodeficiency Job’s syndrome. Allogeneic Hematopoietic Stem Cell Transplantation
(HSCT) has shown promise in correction of the underlying immunological defect, with
one report suggesting HSCT can prevent development of wider connective tissue
complications. Here, we report the case of a 26 year old male who developed an
acute ST-elevation myocardial infarction due to coronary artery ectasia and thrombosis,
occurring despite pediatric allogeneic HSCT for STAT3-HIES and a predicted 10-year
conventional cardiovascular risk of 0.1%. Vasculopathy associated with STAT3-HIES
may persist or arise following HSCT and can precipitate life-threatening complications.
This has implications for counseling and vascular surveillance, and highlights the need
for further studies to determine the risk, pathogenesis, and optimal management of the
vasculopathy associated with STAT3-HIES.
Keywords: Job’s syndrome, STAT3 transcription factor, ST elevation myocardial infarction, coronary vessels,
thrombosis, cardiovascular diseases, hematopoietic stem cell transplantation, counseling
INTRODUCTION
“Job’s syndrome” was first coined in 1966 by Davis et al. to describe the constellation of childhood-
onset dermatitis, recurrent staphylococcal “cold” skin abscesses, and chronic sinopulmonary
disease accompanied by extreme elevation of immunoglobulin IgE (1). Dominant negative
mutations in the transcription factor STAT3 underlie ∼75% of sporadic or autosomal dominant
“hyper IgE syndromes” (HIES) (2–5), and give rise to a wide range of multi-system complications
(6). These include vascular abnormalities, scoliosis, facial dysmorphism, osteoporosis, and
retained primary teeth, accompanied by elevated malignancy risk (6). Defective wound healing
aggravates recurrent pulmonary infections, accelerating respiratory decline, and mortality risk (7).
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Multi-disciplinary care and treatments, including antimicrobial
prophylaxis and immunoglobulin replacement therapy (IgRT),
is aimed at slowing this decline. Allogeneic hematopoietic
stem cell transplantation (HSCT) has been used in a small
but growing number of cases, prompted by hematological
malignancy or infection-burden and parenchymal lung damage
despite conventional therapy. These demonstrate a role for
HSCT in resolving the immunological deficit and modifying
pulmonary decline in selected STAT3-HIES patients (8–11).
HSCT has also been suggested to halt or delay development
of extra-hematological manifestations of STAT3-HIES “including
neurological, musculoskeletal, and vascular abnormalities” when
conducted in adolescence (12). With increasing interest in the
curative potential of HSCT, accurate description of the limits
and potential of HSCT is timely (13) and carries significant
implications for patients, families, clinicians, and healthcare
commissioners. Here, we report in detail the acute myocardial
infarction in a patient with genetically-confirmed STAT3-HIES,
due to thrombosis of an ectatic coronary artery, despite
uncomplicated allogeneic HSCT conducted in childhood. We
reviewed medical case notes to determine the patient’s pre-
morbid cardiovascular disease (CVD) risk score, and surveyed
the literature to address issues raised by this case concerning
HSCT, vasculopathy, and cardiovascular outcomes in relation
to STAT3-HIES. The following Medline search terms were used
(“myocardial infarction” OR “vasculopathy” OR aneurysm OR
rupture) AND (STAT3 OR “signal transducer and activator of
transcription 3” OR “Hyper IgE Syndrome” OR “HIES”) on
06-MAY-2020 to identify the state of published knowledge.
Case Report
A young Caucasian male was diagnosed with Job’s syndrome
age 6 years on the background of neonatal onset dermatitis
with boils, recurrent sino-pulmonary infections, and IgE
>6,000 kU/L (normal <56). STAT3-HIES was confirmed on
the basis of an NIH score of 76 (14) and Sanger sequencing
demonstrating heterozygous state for 1144C>T (R382W);
a common mutation interfering with the DNA-binding
domain of STAT3. Despite antimicrobial prophylaxis and IgRT,
he experienced frequent severe broncho-pneumonias with
progressive bilateral bronchiectasis. On this basis, he underwent
myeloablative HSCT aged 13 years with Alemtuzumab,
Fludarabine, Melphalan conditioning. Subsequent to HSCT,
he showed 100% donor chimerism in all hematopoietic cell
lineages, normalization of vaccination responses and marked
decline in serum IgE from 8,778 kU/L to 176.0 kU/L (8).
IL17A production and Th17 subsets normalized post HSCT (8).
Following an initial diagnosis of delayed puberty secondary to
chronic childhood illness, he was commenced on testosterone
replacement therapy under specialist endocrine monitoring.
He was able to cease immunoglobulin replacement and graft
vs. host disease prophylaxis, and gained full-time employment,
maintained on prophylactic azithromycin, fluticasone nasal
spray, vitamin D, with annual zoledronate therapy. He remains
under care of the All Wales HSCT multi-disciplinary team.
Over a decade following HSCT, he developed sudden-
onset central chest pain waking him from sleep. Emergency
department electrocardiogram showed widespread anterior ST-
elevation, associated with a 3 h troponin rise from 26 to 43,249
ng/L. Full blood count, CRP, and ESR were within normal
limits with a total cholesterol of 4.8 mmol/L (<5), non-fasted
LDL-cholesterol 3.3 mmol (<3.0), HDL-cholesterol 1.1 mmol/L
(>1.0), and triglyceride 0.8 mmol/L (<2.0). At routine clinic
review 1 month prior, he was normotensive (126/84 mmHg)
with BMI 23.1 kg/m2. There was no specific family history
of premature CAD, arrhythmia, or sudden cardiac death and
no prior history of Kawasaki’s disease. Aged 26 years, as a
life-long non-smoker with no history of illicit drug use, his
predicted 10-year risk of heart attack or stroke based on UK-
population datasets (QRISK3) was 0.1% (15). He received a
diagnosis of ST-elevation myocardial infarction (STEMI) and
underwent urgent primary percutaneous coronary intervention
within 12 h of symptom onset. Angiography revealed proximal
ectasia leading on to mid-vessel occlusion of his left anterior
descending (LAD) coronary artery, with otherwise unobstructed
coronary vessels (Figure 1; Supplementary Video 1). Intra-
coronary thrombolysis using tissue plasminogen activator along
with mechanical aspiration of thrombus led to restoration
of flow in the LAD (Figure 2; Supplementary Videos 2, 3).
No underlying stenosis at the point of the initial vessel
occlusion was noted, hence thrombus formation in the ectatic
proximal LAD with distal embolization and occlusion of
the mid LAD was felt to be the likely mechanism of his
presentation with STEMI. Dual pathway blockade (coagulation
and platelet inhibition) was initiated to offer protection against
recurrence of coronary thrombotic occlusion (16, 17) with
aspirin 75mg for 3 months, rivaroxaban 2.5mg twice daily
for 3 years and clopidogrel 75mg long term. Atorvastatin,
candesartan, bisoprolol, ivabradine, and spironolactone were
also initiated. Echocardiography 1 week post-STEMI showed
moderate reduction in left ventricular systolic function with
anteroseptal and apical akinesis (Supplementary Video 4). At
12 months, Simpson’s biplane ejection fraction remains reduced
at 41%, with aneurysmal dilatation of the ventricular apex
and persistent regional wall motion abnormalities consistent
with mild-moderate systolic impairment. Contrast computed
tomography (CT) revealed a bovine aortic arch (a common
variant), but no evidence of intra-cranial arterial aneurysms.
Examination of the retinal vasculature was also normal.
What Is the Significance of Vasculopathy in
STAT3-HIES?
Concerns around vasculopathy in AD-HIES first emerged in
2007, after report of subarachnoid hemorrhage and myocardial
infarctions in relatively stable patients (18). A systematic review
conducted in 2010 identified vascular abnormalities in a total
of 8 patients with clinically-defined AD-HIES patients from the
international literature. Abnormalities included aortic aneurysm
(n = 1), coronary aneurysms (n = 3), congenital patent ductus
venosus (n = 2), and intracranial vascular abnormalities (n =
2). Mortality in 3 of these patients followed aneurysm rupture,
myocardial infarction, or thrombotic stroke, with additional
stroke-related morbidity (7, 19). Five patients with a clinical
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diagnosis of AD HIES are described in a Taiwanese cohort.
One death occurred due to acute myocardial infarction with
dilated coronary artery in a 13 year old male (20). Additional
case reports describe symptomatic aortic and cerebral aneurysms
in pediatric (21, 22) and adults but with limited genetic and
follow-up information. Subsequent cross-sectional studies within
genetically-defined STAT3-HIES US (National Institute for
Health) and French cohorts have provided convincing evidence
for widespread “vasculopathy” in STAT3-HIES. In 59 patients
imaged from infancy to adulthood (8 to 57 years), intracranial
FIGURE 1 | Proximal ectasia (*) revealed by angiography.
aneurysms were present in 20%; coronary artery abnormalities
(tortuosity, ectasia, or aneurysm) in 70%; and brain abnormalities
(white matter hyperintensities, lacunar lesions, and atrophy) in
95% (23–25). Rates of coronary artery tortuosity increased with
age (23). Deep venous thrombosis events were also reported in
3/21 patients (aged 28–39), with 2 of these also experiencing
pulmonary embolism (25).
The clinical significance and optimal approach to such
frequent and widespread vascular abnormalities remains an area
of active investigation. Cerebral white matter hyperintensities
are associated with an increased risk of dementia in the general
population (26). Detailed neurocognitive behavioral profiling
in STAT3-HIES has revealed subtle relative impairment of
memory and executive functioning measures, despite average
to high average overall cognitive function (24). Antiplatelet
therapy has been suggested to reduce the risk of coronary artery
thrombosis and cerebral microvascular disease (25), however
may actually be harmful given prior reports of pulmonary
TABLE 1 | Key learning points and clinical knowledge gaps highlighted by
this case.
Learning points Clinical knowledge gaps
• Vascular pathology associated with
STAT3-HIES can cause life
threatening illness.
• Hematopoietic stem cell
transplantation (HSCT) does not
appear to prevent this
complication.
• What is the natural history and clinical
significance of vasculopathy?
• Should vascular screening be offered to
patients with STAT3-HIES?
• Does impairment to cutaneous and lung
healing extend to other (cardiac and
cerebral) tissues?
• What are the long-term sequelae of
cerebral white matter hyperintensities in
the aging STAT3-HIES patient group?
• Can a molecularly-targeted approach
normalize STAT3 signaling pathways
across tissues?
FIGURE 2 | (A) Catherization of the left coronary circulation reveals occlusion of left anterior descending (LAD) coronary artery. The radio-opaque tip of the angioplasty
wire (*) can been seen in distal LAD having traversed the site of thrombotic occlusion in mid LAD. (B) Flow restoration following intra-coronary thrombolysis and
mechanical thrombus aspiration.
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hemorrhage-associated mortality (7). Similarly, an international
consensus on approach to intra-cranial aneurysms remains
elusive. The detection rate of 20% in STAT3-HIES matches
that found by the Familial Intracranial Aneurysm (FIA) study
(27). It is relevant to consider this benchmark, given the FIA
study only offered vascular screening to those perceived as
“high risk” for aneurysm detection (i.e., first-degree relatives
of those affected by intra-cranial aneurysm, aged ≥30 years of
age, with smoking and/or hypertensive history). Of these, 10%
subsequently underwent surgical or endovascular intervention
(27). Vascular imaging studies in 59 patients within STAT3-HIES
led to a similar proportion of asymptomatic aneurysms being put
forward for endovascular coiling (23, 25). How patients, families,
and clinicians affected by STAT3-HIES currently perceive and
approach vascular risk in routine clinical practice is unclear. A
recent report from the US Immunodeficiency Disease Network
concerning 85 patients indicates a low uptake of vascular
screening in asymptomatic STAT3-HIES patients (<10%) across
the US and Canada, outside of the NIH. Aneurysm rupture
rates and outcomes in this rare disease population will be
important–if challenging–to quantify, as this information is vital
to inform discussions concerning interventional approaches.
Endovascular coiling or neurosurgical clipping both carry a
risk of death or disability, up to 5% (25). Peri-procedural
risk is further heightened when performed following acute
rupture (25), suggesting this decision is best made early. The
consequence of delay is illustrated by the rupture of a giant basilar
artery aneurysm in one individual with Job’s, causing death
shortly prior to the scheduled endovascular procedure, aged 35
years. Additional approaches to modify the risk of aneurysms
development and rupture are therefore desirable. Detailed in vivo
sonographic assessment of seemingly normal carotid vessels in
STAT3-HIES patients revealed reduced intima-media thickness
(IMT) and subtly increased internal carotid diameter, relative
to healthy controls. Circumferential wall stress correlated with
frequency and severity of vasculopathy, unlike genotype or NIH
Score (a surrogate for degree of multi-system involvement) (25).
Under laminar blood flow conditions, circumferential wall stress
(CWS) increases proportionally to mean arterial blood pressure,
highlighting both a potential biomarker and modifiable risk
factor. Hypertension in the NIH cohort appeared more common
than expected for age, with an overall incidence of 42% despite
a mean age of 31 (23), but was not a clear driver within the
normotensive French cohort (25).
What Evidence Is There That HSCT Can
Ameliorate Vascular Pathology?
A clearer understanding of the underlying pathophysiology of
vasculopathy in STAT3-HIES will help identify new therapies,
and address if HSCT might feasibly be expected to halt their
development. In the context of a hypertensive (angiotensin II-
driven) murine model of abdominal aortic aneurysm, inhibition
of IL-17A signaling promotes inflammatory T-cell infiltration
and drives aneurysm growth and rupture (25). Deficiency of IL-
17 producing Th17 cells is a pathognomonic feature of STAT3-
HIES (28), and their restoration suggests a plausible mechanism
by which HSCT might ameliorate non-haematopoietic vascular
manifestations. Immune reconstitution with normalization of
IgE and detectable levels of IL17+ CD4+ T-cells are consistent
features across published HSCT case series (8, 11, 12, 29),
including by Goussetis et al. This group reported follow-up of
2 unrelated males with STAT3-HIES following myeloablative
matched-sibling HSCT aged 15 and 16 years for high grade Non-
Hodgkin Lymphoma (12). Both carried pathogenic mutations in
the DNA-binding domain of STAT3 (R382Q or R382W). Follow-
up until the ages of 29 and 26 years (respectively), failed to
detect any coronary artery aneurysms or brain lesions; leading
the authors to suggest HSCT “cures patients with autosomal
dominant hyper-IgE syndrome.”
This contrasts with our patient’s experience of life-threatening
coronary artery thrombosis despite undergoing allogeneic HSCT
at younger age, with similar mutation type and follow-up
duration. Several possibilities may explain these contradictory
outcomes, notably the limited sample size, disease-phenotype
variability, and distinct HSCT indication and conditioning. We
suggest differences in vascular imaging methodology are also
important to highlight. Echocardiography was used to screen
for coronary artery abnormalities in the prior report (personal
communication: Drs Oikonomopoulou & Goussetis, January
2020), whereas ectasia was recognized in our patient following
invasive coronary angiography. These approaches differ in
sensitivity, with echocardiography becoming progressively less
accurate for coronary artery imaging with age (30). Coronary
artery multidetector computed tomography (CT) angiography
is increasingly preferred in adults, and is part of the screening
for STAT3-HIES patients over 30 years of age under care
of the NIH (https://clinicaltrials.gov/ct2/show/NCT00006150).
Magnetic resonance (MR) imaging offers an non-ionizing
alternative, and enables additional in vivo coronary vessel wall
(VW) imaging in patients able to tolerate this procedure, and
is utilized for screening and follow-up of the majority of the
STAT3-HIES patients followed at NIH (31).
What Is the Primary Driver for Vascular
Abnormalities in STAT3-HIES?
Infection susceptibility is a core diagnostic feature of primary
immunodeficiency disorders. Wider causes of hyper IgE
syndromes, such as recessive DOCK8 and X-linked WASP
deficiency [reviewed Ponsford et al. (32)] are distinctive
for marked viral susceptibility and high rates of childhood-
onset complications including vasculitis, encephalitis, and
stroke-related morbidity/mortality (33). In this genetic-setting,
allogenic HSCT clearly offers significant benefit (34), suggesting
correction of infection susceptibility is relevant. Limited
post-mortem studies in genetically-confirmed STAT3-HIES
have provided mixed results in relation to infective triggers.
Opportunistic fungal infection (Scedosporium prolificans or
Aspergillus fumigatus) were identified within the brains of 2 of 6
patients postmortem (7). Notably, these patients also had history
of cystic lung disease and active pneumonia at time of death.
Retrospective analysis in this setting maybe vulnerable to the cum
hoc ergo propter hoc (with this, therefore because of this) fallacy.
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Detailed neuropathological examination of a single patient who
died from giant basilar artery aneurysm rupture, in the absence
of overt fungal pneumonia, identified no evidence of vasculitis
or inflammation within the vessel wall of aneurysmal and non-
dilated cerebral blood vessels (25, 35). Furthermore, infective
causes of aneurysms were not apparent in any of the 59 STAT3-
HIES patients imaged (23, 25). These observations do not exclude
an infective etiology for vasculopathy in STAT3-HIES, but are
suggestive of an intrinsic role for STAT3 in vascular health.
This is supported by other monogenic disorders presenting
with similar connective tissue abnormalities but without marked
infection susceptibility. Loeys-Dietz syndrome (LDS) is caused
by autosomal dominant mutations in the transforming growth
factor β (TGF-β) receptor pathway. Affected individuals present
with atopic tendency and a Marfan-like syndrome that includes
familial thoracic aortic aneurysms associated with increased
TGF-β signaling within the vessel wall (36). The role of TGF-
β1 as a master regulator of matrix metalloproteinases (37) also
fits with the dysregulation of these mediators of extracellular
remodeling observed in STAT3-HIES (38). Further research at
this interface of atopic and syndromic disease has revealed a
molecular link between STAT3 and TGF-β (39). The ERBB2-
interacting protein (ERBIN) allows STAT3 to negatively regulate
TGF-β; loss of ERBIN leads to excessive TGF-β signaling and
predicts similar in STAT3 deficiency states. Exaggerated TGF-β
protein expression has indeed been documented within post-
mortem cerebral arteries in STAT3-HIES (25). Hypertension, via
biomechanical forces such as shear stress, has also been shown to
promote oxidative stress and heighten TGF-β expression during
pathological arterial remodeling (40). If correct, a tissue intrinsic
role for STAT3 has several implications. Firstly, it suggests
modulation of TGF-β signaling represents a promising target for
therapeuticmodulation. Secondly, it implies that correction of the
hematopoietic stem compartment alone (via HSCT or current
gene therapy approaches) cannot correct dysregulated signaling
due to pathogenic STAT3 carried within the vascular endothelial
and smooth muscle cells. This is consistent with the events
observed our patient, and leads to the next question relevant to
our case.
What Role Does STAT3 Play in the Heart?
Convergent evidence supports a critical role for STAT3 in
cardiac function. Targeted deletion of murine Stat3 within
cardiomyocytes (cardiac-Stat3−/−) has been used to circumvent
embryonic mortality of complete knockout, and facilitate
assessment of its cardiac-intrinsic roles. Cardiac-Stat3−/− mice
spontaneously develop heart dysfunction with advancing age
associated with a dramatic increase in cardiac fibrosis (41).
Of particular relevance to our patients’ clinical presentation,
outcomes following ischemic-reperfusion injury or permanent
left coronary artery ligation are significantly worsened relative
to wild type (WT) littermates. Following complete ligation,
progressive decline in left ventricular systolic function in these
mice was accompanied by massive fibrosis, dilatation, and
symptomatic heart failure. At 6-months, mortality in cardiac-
Stat3−/− mice was 100%, compared to 32% in the WT group.
Heterozygotes expressing reduced levels of protein appeared
unaffected (42). Together, this is consistent with a critical
cardioprotective role for STAT3 within the myocardium, that is
sensitive to gene dosage effects. Additional complexity exists with
regard to myocardial healing (43) and thrombosis risk, given
impaired neutrophil chemotaxis (42) and dampened platelet
activation (44) accompany STAT3-HIES. Thus, the significance
of dominant negative STAT3 mutations in the context of aging
and ischaemic insult have yet to be systematically determined.
Fortuitously, a murine model carrying a common human STAT3
pathogenic mutation is now available to address this (45). This
recapitulates multiple aspects of human pathology, including
extreme elevation of IgE, Th17 cell deficiency, and bacterial
infection susceptibility. In this setting, immune reconstitution
does not fully correct the in vivo susceptibility of these animals
to bacterial infection (45), nor rescues cutaneous wound healing
defects (46). This is echoed by real-life experience of HSCT,
which suggests a reduced infection frequency but ongoing
abnormal pulmonary remodeling in terms of pneumatocele
development (8, 11). It remains to be seen how/if this transgenic
model recapitulates wider aspects of human vasculopathy such
as tortuosity and dilatation that will allow dissection of the
contribution of infective and environmental stimuli and support
pre-clinical evaluation.
FUTURE DIRECTIONS
Our understanding of the pathogenesis of vasculopathy in
Job’s is shaped by developing model systems and detailed
clinical observation of Nature’s own experiments. The study
of rare disease frequently necessitates collaboration to achieve
this. An international survey via the European Society for
Immunodeficiencies (ESID) will shortly be commencing to
address clinical knowledge gaps identified in this report
(Table 1). We hope this case will encourage readers involved
with care for patients with STAT3-HIES to engage with this,
thus supporting the most representative insight to natural
history of STAT3-HIES to date. Epidemiological information
provided is intended to help inform clinical decision making,
and is likely to prove timely given advances in precision
medicine. Analysis of prospective longitudinal vascular imaging
pre- and post-HSCT will be required to definitively answer
the potential and limitations of this therapy. A clearer
understanding of molecular pathology may support targeted
therapeutic strategies, promising what current approaches have
yet to convincingly deliver: a holistic therapy for the multi-
system complications afflicting those with STAT3-HIES. Whilst
TGF-β appears a relevant target, given the range of complex
signaling pathways integrated via STAT3, additional “master
regulators” of interest are also likely to emerge. The creation
of STAT3-HIES patient-derived pluripotent stem-cell lines (47)
now permits unprecedented insights to the downstream effects
of dysregulated STAT3 signaling on cellular transcriptional
networks, across a range of relevant human cell types.
This approach has recently identified deficiency of hypoxia-
inducible factor (HIF1α) as central to defects in extracellular
matrix remodeling and angiogenesis (48). Furthermore, use
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of the HIF1α stabilizing medications Dimethyl Fumarate and
Daprodustat normalized wound healing in the STAT3-HIES
mouse model in vivo, and promoted differentiation of naïve
CD4+ T-cells isolated from STAT3-HIES patients into Th17 cells
ex vivo (48). Careful evaluation will be required to assess if
this approach can be safely translated into the clinic. Targeted
therapies have already shown tremendous benefit in other
monogenic disorders in the field of primary immunodeficiency
(49, 50), and promise an exciting new chapter in the book
of Job.
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